Saturation Mutagenesis of the HIV-1 Envelope CD4 Binding Loop Reveals Residues Controlling Distinct Trimer Conformations

PLoS Pathogens

Volumn 12, Issue 11, 2016, Pages

  Duenas Decamp, Maria ^a   Jiang, Li ^a   Bolon, Daniel ^a   Clapham, Paul R ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD4 ANTIBODY; EPITOPE; GLYCAN; GLYCOPROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VACCINE; CD4 ANTIGEN; GLYCOPROTEIN GP 120; VIRUS RNA;

AMINO ACID SEQUENCE; ARTICLE; CHEMICAL BINDING; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; MUTAGENESIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMID; PROTEIN FUNCTION; PROTEIN STRUCTURE; TROPISM; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INFECTIVITY; BINDING SITE; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEK293 CELL LINE; IC50; IMMUNOLOGY; PROTEIN CONFORMATION; VIROLOGY;

ANTIGENS, CD4; BINDING SITES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEK293 CELLS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MACROPHAGES; MUTAGENESIS; PROTEIN CONFORMATION; RNA, VIRAL;

EID: 85001967895     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005988     Document Type: Article

References (52)

1. Wilen CB, Tilton JC, Doms RW, Molecular mechanisms of HIV entry. Adv Exp Med Biol. 2012;726:223–42. doi: 10.1007/978-1-4614-0980-9_1022297516
2. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA, Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998;393:648–59. doi: 10.1038/314059641677
3. Madani N, Schon A, Princiotto AM, Lalonde JM, Courter JR, Soeta T, et al. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure. 2008;16:1689–701. doi: 10.1016/j.str.2008.09.00519000821
4. Haim H, Strack B, Kassa A, Madani N, Wang L, Courter JR, et al. Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity. PLoS Pathog. 2011;7:e1002101. doi: 10.1371/journal.ppat.100210121731494
5. Xiang SH, Kwong PD, Gupta R, Rizzuto CD, Casper DJ, Wyatt R, et al. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol. 2002;76:9888–99. doi: 10.1128/JVI.76.19.9888-9899.200212208966
6. Peters PJ, Bhattacharya J, Hibbitts S, Dittmar MT, Simmons G, Bell J, et al. Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages. J Virol. 2004;78:6915–26. doi: 10.1128/JVI.78.13.6915-6926.200415194768
7. Peters PJ, Duenas-Decamp MJ, Sullivan WM, Brown R, Ankghuambom C, Luzuriaga K, et al. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. Retrovirology. 2008;5:5. doi: 10.1186/1742-4690-5-518205925
8. Duenas-Decamp MJ, Peters PJ, Burton D, Clapham PR, Determinants flanking the CD4 binding loop modulate macrophage tropism of human immunodeficiency virus type 1 R5 envelopes. J Virol. 2009;83:2575–83. doi: 10.1128/JVI.02133-0819129457
9. Dunfee RL, Thomas ER, Gorry PR, Wang J, Taylor J, Kunstman K, et al. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc Natl Acad Sci U S A. 2006;103:15160–5. doi: 10.1073/pnas.060551310317015824
10. Musich T, Peters PJ, Duenas-Decamp MJ, Gonzalez-Perez MP, Robinson J, Zolla-Pazner S, et al. A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection. J Virol. 2011;85:2397–405. doi: 10.1128/JVI.02187-1021159865
11. Walter BL, Wehrly K, Swanstrom R, Platt E, Kabat D, Chesebro B, Role of low CD4 levels in the influence of human immunodeficiency virus type 1 envelope V1 and V2 regions on entry and spread in macrophages. J Virol. 2005;79:4828–37. doi: 10.1128/JVI.79.8.4828-4837.200515795268
12. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science. 2013;342:1477–83. doi: 10.1126/science.124562524179159
13. Hietpas R, Roscoe B, Jiang L, Bolon DN, Fitness analyses of all possible point mutations for regions of genes in yeast. Nat Protoc. 2012;7:1382–96. doi: 10.1038/nprot.2012.06922722372
14. Hietpas RT, Bank C, Jensen JD, Bolon DN, Shifting fitness landscapes in response to altered environments. Evolution. 2013;67:3512–22. doi: 10.1111/evo.1220724299404
15. Hietpas RT, Jensen JD, Bolon DN, Experimental illumination of a fitness landscape. Proc Natl Acad Sci U S A. 2011;108:7896–901. doi: 10.1073/pnas.101602410821464309
16. Jiang L, Mishra P, Hietpas RT, Zeldovich KB, Bolon DN, Latent effects of Hsp90 mutants revealed at reduced expression levels. PLoS Genet. 2013;9:e1003600. doi: 10.1371/journal.pgen.100360023825969
17. Wagenaar TR, Ma L, Roscoe B, Park SM, Bolon DN, Green MR, Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain. Pigment cell & melanoma research. 2014;27:124–33.
18. Roscoe BP, Thayer KM, Zeldovich KB, Fushman D, Bolon DN, Analyses of the effects of all ubiquitin point mutants on yeast growth rate. J Mol Biol. 2013;425:1363–77. doi: 10.1016/j.jmb.2013.01.03223376099
19. Duenas-Decamp MJ, Clapham PR, HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody, 2G12. J Virol. 2010;84: 9608–12. doi: 10.1128/JVI.00185-1020610714
20. Duenas-Decamp MJ, Peters P, Burton D, Clapham PR, Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop. J Virol. 2008;82:5807–14. doi: 10.1128/JVI.02585-0718385254
21. Peters PJ, Sullivan WM, Duenas-Decamp MJ, Bhattacharya J, Ankghuambom C, Brown R, et al. Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis. J Virol. 2006;80:6324–32. doi: 10.1128/JVI.02328-0516775320
22. Sturdevant CB, Joseph SB, Schnell G, Price RW, Swanstrom R, Spudich S, Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection. PLoS Pathog. 2015;11:e1004720. doi: 10.1371/journal.ppat.100472025811757
23. Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R, HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog. 2011;7:e1002286. doi: 10.1371/journal.ppat.100228622007152
24. Peters PJ, Gonzalez-Perez MP, Musich T, Moore Simas TA, Lin R, Morse AN, et al. Infection of ectocervical tissue and universal targeting of T-cells mediated by primary non-macrophage-tropic and highly macrophage-tropic HIV-1 R5 envelopes. Retrovirology. 2015;12:48. doi: 10.1186/s12977-015-0176-226055104
25. Isaacman-Beck J, Hermann EA, Yi Y, Ratcliffe SJ, Mulenga J, Allen S, et al. Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J Virol. 2009;83:8208–20. doi: 10.1128/JVI.00296-0919515785
26. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med. 2009;206:1273–89. doi: 10.1084/jem.2009037819487424
27. Joseph SB, Swanstrom R, Kashuba AD, Cohen MS, Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. Nat Rev Microbiol. 2015;13:414–25. doi: 10.1038/nrmicro347126052661
28. Meyerson JR, Tran EE, Kuybeda O, Chen W, Dimitrov DS, Gorlani A, et al. Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives. Proc Natl Acad Sci U S A. 2013;110:513–8. doi: 10.1073/pnas.121481011023267106
29. Tran EE, Borgnia MJ, Kuybeda O, Schauder DM, Bartesaghi A, Frank GA, et al. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog. 2012;8:e1002797. doi: 10.1371/journal.ppat.100279722807678
30. O'Connell O, Repik A, Reeves JD, Gonzalez-Perez MP, Quitadamo B, Anton ED, et al. Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism. J Virol. 2013;87:187–98. doi: 10.1128/JVI.01834-1223055568
31. Dey B, Pancera M, Svehla K, Shu Y, Xiang SH, Vainshtein J, et al. Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J Virol. 2007;81:5579–93. doi: 10.1128/JVI.02500-0617360741
32. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol. 2004;78:13232–52. doi: 10.1128/JVI.78.23.13232-13252.200415542675
33. Hoffman TL, LaBranche CC, Zhang W, Canziani G, Robinson J, Chaiken I, et al. Stable exposure of the coreceptor-binding site in a CD4-independent HIV- 1 envelope protein. Proc Natl Acad Sci U S A. 1999;96:6359–64. 10339592
34. Boyd DF, Peterson D, Haggarty BS, Jordan AP, Hogan MJ, Goo L, et al. Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer. J Virol. 2015;89:894–907. doi: 10.1128/JVI.02680-1425378497
35. Murphy MK, Yue L, Pan R, Boliar S, Sethi A, Tian J, et al. Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog. 2013;9:e1003173. doi: 10.1371/journal.ppat.100317323468623
36. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target. Science. 2009;326:285–9. doi: 10.1126/science.117874619729618
37. Munro JB, Gorman J, Ma X, Zhou Z, Arthos J, Burton DR, et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science. 2014;346(6210):759–63. doi: 10.1126/science.125442625298114
38. Zwick MB, Burton DR, HIV-1 neutralization: mechanisms and relevance to vaccine design. Curr HIV Res. 2007;5:608–24. 18045117
39. Gonzalez-Perez MP, O'Connell O, Lin R, Sullivan WM, Bell J, Simmonds P, et al. Independent evolution of macrophage-tropism and increased charge between HIV-1 R5 envelopes present in brain and immune tissue. Retrovirology. 2012;9:20. doi: 10.1186/1742-4690-9-2022420378
40. Thomas ER, Dunfee RL, Stanton J, Bogdan D, Taylor J, Kunstman K, et al. Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology. 2007;360:105–19. doi: 10.1016/j.virol.2006.09.03617084877
41. Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, Feng Y, et al. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol. 2011;85:8954–67. doi: 10.1128/JVI.00754-1121715490
42. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011;333:1633–7. doi: 10.1126/science.120722721764753
43. Scharf L, Wang H, Gao H, Chen S, McDowall AW, Bjorkman PJ, Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env. Cell. 2015;162:1379–90. doi: 10.1016/j.cell.2015.08.03526359989
44. Li H, Wang S, Kong R, Ding W, Lee FH, Parker Z, et al. Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc Natl Acad Sci U S A. 2016;113:E3413–22. doi: 10.1073/pnas.160663611327247400
45. Li MZ, Elledge SJ, SLIC: a method for sequence- and ligation-independent cloning. Methods Mol Biol. 2012;852:51–9. doi: 10.1007/978-1-61779-564-0_522328425
46. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46:1896–905. doi: 10.1128/AAC.46.6.1896-1905.200212019106
47. Musich T, O'Connell O, Gonzalez-Perez MP, Derdeyn CA, Peters PJ, Clapham PR, HIV-1 non-macrophage-tropic R5 envelope glycoproteins are not more tropic for entry into primary CD4+ T-cells than envelopes highly adapted for macrophages. Retrovirology. 2015;12:25. doi: 10.1186/s12977-015-0141-025809903
48. Guo W, Cleveland B, Davenport TM, Lee KK, Hu SL, Purification of recombinant vaccinia virus-expressed monomeric HIV-1 gp120 to apparent homogeneity. Protein Expr Purif. 2013;90:34–9. doi: 10.1016/j.pep.2013.04.00923665667
49. Moore JP, Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4. Aids. 1990;4:297–305. 2190604
50. Ringe RP, Sanders RW, Yasmeen A, Kim HJ, Lee JH, Cupo A, et al. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A. 2013;110:18256–61. doi: 10.1073/pnas.131435111024145402
51. Guo J, Wang W, Yu D, Wu Y, Spinoculation triggers dynamic actin and cofilin activity that facilitates HIV-1 infection of transformed and resting CD4 T cells. J Virol. 2011;85:9824–33. doi: 10.1128/JVI.05170-1121795326
52. O'Doherty U, Swiggard WJ, Malim MH, Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol. 2000;74:10074–80. 11024136